-
公开(公告)号：US20240376199A1
公开(公告)日：2024-11-14
申请号：US18691229
申请日：2022-09-13
Inventor： Zhiqiang AN , Ningyan ZHANG , Peng ZHAO
IPC: C07K16/28
Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments etc., that specifically bind a TREM2 protein or a TREM2 protein epitope, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
-
公开(公告)号：US20240101667A1
公开(公告)日：2024-03-28
申请号：US18255745
申请日：2021-12-02
Inventor： Chengcheng ZHANG , Guojin WU , Jaehyup KIM , Heyu CHEN , Mi DENG , Zhiqiang AN , Ningyan ZHANG , Ryan HUANG
IPC: C07K16/28 , A61P35/02 , G01N33/574 , G01N33/577
CPC classification number: C07K16/2803 , A61P35/02 , G01N33/574 , G01N33/577 , A61K2039/505 , C07K2317/24 , C07K2317/76 , C07K2317/92
Abstract: Provided herein are methods and compositions for the identification of modulators of LILRB3 activation. Also provided herein are methods of treating cancer comprising the administration of an inhibitor LILRB3 activation. Also provided are methods of treating autoimmune disease or inhibiting the onset of transplant rejection or treating an inflammatory disorder comprising administering an agonist of LILRB3 activation to a subject.
-
公开(公告)号：US20240059647A1
公开(公告)日：2024-02-22
申请号：US18173413
申请日：2023-02-23
Inventor： Kyoji TSUCHIKAMA , Yasuaki ANAMI , Chisato TSUCHIKAMA , Ningyang ZHANG , Zhiqiang AN
IPC: C07C247/04 , A61K47/68 , A61P35/00 , A61K31/40 , C07D209/20 , C07D403/12
CPC classification number: C07C247/04 , A61K47/6889 , A61P35/00 , A61K31/40 , C07D209/20 , C07D403/12 , A61K45/06
Abstract: In one aspect, the present disclosure provides compounds of the formula:
wherein the variables are as defined herein.
In another aspect, the present disclosure provides compounds of the formula:
wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure provides antibody drug conjugates comprising compounds of the present disclosure. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds and anti-body drug conjugates disclosed herein.-
公开(公告)号：US20230235055A1
公开(公告)日：2023-07-27
申请号：US18007185
申请日：2021-07-26
Inventor： Zhiqiang AN , Chengcheng ZHANG , Ningyan ZHANG , Yuanzhi CHEN , Heyu CHEN
IPC: C07K16/28 , A61K45/06 , G01N33/574 , A61K39/395 , A61P35/00
CPC classification number: C07K16/2803 , A61K45/06 , G01N33/57484 , A61K39/3955 , A61P35/00 , C07K2317/21 , C07K2317/24 , C07K2317/73 , A61K2039/505
Abstract: Provided herein are antibodies binding to LILRB1 and the uses of the antibodies in detecting and treating cancer and autoimmune diseases.
-
Patent Agency Ranking
公开(公告)号：US20220056124A1
公开(公告)日：2022-02-24
申请号：US17273538
申请日：2019-09-05
Inventor： Ningyan ZHANG , Dawei BU , Zhiqiang AN , Hui DENG , Philipp E. SCHERER
Abstract: Aspects of the present invention relate to methods and reagents for increasing chemosensitivity to platinum-based chemotherapy. In one aspect, a method of increasing chemosensitivity to platinum-based chemotherapy is provided, comprising administering to a patient in need thereof an effective amount of an endotrophin-neutralizing agent. The agent can be a monoclonal antibody, or fragment thereof, capable of binding to the C5 domain of the alphas chain of collagen VI. In some embodiments, the method can further include administering an effective amount of thiazolidinedione to said patient.
-
公开(公告)号：US20210371508A1
公开(公告)日：2021-12-02
申请号：US17332790
申请日：2021-05-27
Inventor： Ningyan ZHANG , Zhiqiang AN , Zhiqiang KU , Yihong WAN , Jing KRZESZINSKI
IPC: C07K16/18 , A61K45/06 , G01N33/574 , A61K47/68
Abstract: Provided herein are methods for treating cancer, such as breast cancer, by administering an inhibitor of NMES1. Further provided herein are NMES1 monoclonal antibodies which may be used to detect or treat cancer.
-
公开(公告)号：US20200055954A1
公开(公告)日：2020-02-20
申请号：US16441350
申请日：2019-06-14
Inventor： Ningyan ZHANG , Zhiqiang AN
IPC: C07K16/32 , G01N33/574 , A61N5/10 , A61K45/06 , A61K39/395 , A61F7/10
Abstract: Isolated or recombinant anti-HER3 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.
-
公开(公告)号：US20180086829A1
公开(公告)日：2018-03-29
申请号：US15696972
申请日：2017-09-06
Inventor： Chengcheng ZHANG , Mi DENG , Wei XIONG , Zhiqiang AN , Ningyan ZHANG , Xun GUI , Junke ZHENG
IPC: C07K16/28 , C07K16/30 , A61P35/02 , A61K45/06 , A61K39/395 , G01N33/574
CPC classification number: C07K16/2803 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61P35/02 , C07K16/3061 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C12N15/1138 , C12N2310/14 , C12N2310/531 , G01N33/57426 , G01N33/57492 , G01N2333/70503
Abstract: The present disclosure is directed to antibodies binding to LILRBs and methods of detecting and treating cancer therewith.
-
29.发明申请公开(公告)号：US20160032011A1
公开(公告)日：2016-02-04
申请号：US14774808
申请日：2014-03-13
Inventor： Ningyan ZHANG , Zhiqiang AN
IPC: C07K16/32 , A61F7/10 , G01N33/574 , A61N5/10 , A61K39/395 , A61K45/06
CPC classification number: C07K16/32 , A61F7/10 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61N5/10 , C07K2317/14 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92 , G01N33/57484 , G01N33/57492
Abstract: Isolated or recombinant anti-HER3 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.
Abstract translation: 提供了分离或重组的抗HER3单克隆抗体。 在一些情况下，实施方案的抗体可用于人类疾病如癌症的检测，诊断和/或治疗治疗。
-
-
-
-
-
-
-
-
Search Results
29
records
(took 0.037 seconds)
